Skip to main
  1. Stocks
  2. Abivax SA
  3. Forecast
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Abivax is supported by highly compelling obefazimod data, with ABTECT-Maintenance showing clinical remission of 51.3% and 50.8% versus 10.4% placebo, plus strong endoscopic benefits and p<0.0001 significance, while longer-term follow-up showed durable efficacy through 144 weeks and no new safety signals over up to seven years of cumulative treatment. Its outlook is further strengthened by broad separation from placebo across advanced-therapy-naive and prior failure subgroups, including prior JAK inhibitor failures, suggesting the drug can address severe ulcerative colitis patients with meaningful unmet need and potential monotherapy utility. The company also appears financially and strategically well positioned, with about €1.2B cash providing runway into 4Q29, a clear commercialization plan targeting ~8,000 gastroenterologists, and a roadmap for Crohn’s data in mid-2027 and NDA submission by YE26.

Bears say

Abivax is viewed cautiously because obefazimod’s encouraging ulcerative colitis data still face a tougher commercial and clinical backdrop, with the next efficacy step increasingly expected to come from combination therapy rather than monotherapy. The company has no announced clinical combination program, while peers are already advancing dual-mechanism approaches and oral competition is intensifying, limiting obefazimod’s ability to break into the first advanced-therapy setting dominated by IL-23 and TL1A regimens. Although Abivax ended the quarter with €402.4MM in cash and €767.1MM of net proceeds, providing runway into 4Q29, the outlook remains pressured by revised commercial assumptions, capital-raise needs, and the view that approval in 4Q27 is already fully priced in.

Abivax SA (ABVX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Abivax SA (ABVX) Analyst Forecast & Price Prediction

Get the latest Abivax SA (ABVX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Abivax SA (ABVX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 11 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $154.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $154.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Abivax SA (ABVX) Analyst Forecast & Price Prediction

Get the latest Abivax SA (ABVX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Abivax SA (ABVX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ABVX stock data and trends